Lactobacillus rhamnosus FMBL L23004 CNN, yogurt starter, yogurt and application thereof

Through the application of C. rhamnosus FMBL L23004 CNN, the problem of insufficient antibacterial activity and inability to grow in milk in the prior art is solved, and effective inhibition of a variety of pathogenic bacteria is achieved and in acid and bile salt environments are achieved. The ability to survive is suitable for yogurt fermentation and the development of healthy products.

CN117660253BActive Publication Date: 2024-11-01SHIHEZI UNIVERSITY
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202311683559.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-10
Publication Date
2024-11-01
Estimated Expiration
2043-12-10

AI Technical Summary

Technical Problem

The existing Lactobacillus rhamnosus has weak antibacterial activity and cannot effectively inhibit a variety of pathogenic bacteria. It cannot grow normally in ordinary milk, which cannot meet the needs of gastrointestinal resistance and antibacterial properties in probiotic products.

Method used

C. rhamnosus C. L23004 CNN is provided, a strain with the ability to inhibit the utilization of intestinal pathogenic bacteria, bile salt resistance, acid resistance and carbohydrate, and is used to prepare drugs, food additives and yogurt fermentation agents that inhibit pathogenic bacteria.

Benefits of technology

This strain can effectively inhibit six pathogenic microorganisms including intestinal pathogenic Escherichia coli and enterotoxin Escherichia coli. It has the ability to survive in acid and bile salt environments, and is also oligomerized against glucose, lactose, and oligomerization of glucose, lactose, and Fructose and galactose oligosaccharides are effective in preventing and treating digestive diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117660253B_ABST
    Figure CN117660253B_ABST
Patent Text Reader

Abstract

The invention relates to the field of biotechnology, and in particular to a Lactobacillus rhamnosus FMBL L23004CNN and an application thereof. The Lactobacillus rhamnosus FMBL L23004CNN was deposited in China Center for Type Culture Collection on June 26, 2023, with a deposit number of CCTCC NO: M 20231099. The Lactobacillus rhamnosus FMBL L23004CNN has good antibacterial effects on enteropathogenic Escherichia coli, enterotoxigenic Escherichia coli, Salmonella enterica subspecies typhimurium, enterohemorrhagic Escherichia coli, Listeria monocytogenes, Salmonella enterica subspecies and the like, and also has acid resistance and bile salt activity, a high survival rate in gastric juice and intestinal juice, good self-aggregation and hydrophobicity, and the ability to utilize carbohydrates. The Lactobacillus rhamnosus FMBL L23004CNN can be used to prepare drugs or food additives for inhibiting pathogenic bacteria, and has broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to Lactobacillus rhamnosus FMBL L23004 CNN, a yogurt starter, yogurt and applications thereof. Background Art

[0002] Lactobacillus rhamnosus, originally a member of the genus Lactobacillus, is now a member of the genus Lactobacillus and is one of the strains certified by the Ministry of Health for addition to food. Lactobacillus rhamnosus has excellent properties such as non-toxicity, no side effects, high intestinal adhesion rate and strong colonization ability. In addition, some strains have important clinical application potentials such as inhibiting spoilage bacteria and pathogens in food, regulating the intestinal flora of the host, improving the body's immunity and anti-cancer, which meets the needs of contemporary people for health and wellness. However, due to its special metabolic pathway, Lactobacillus rhamnosus is different from general lactic acid bacteria and cannot grow normally or proliferate in ordinary milk.

[0003] In production, specific strains of Lactobacillus rhamnosus are usually added to fermented foods such as yogurt and health products or probiotic supplement products. As a fermentation agent, Lactobacillus rhamnosus is often used in the preparation of yogurt fermentation agents and additives for food or health foods. For example, invention patent CN114271328A discloses a yogurt rich in Lactobacillus rhamnosus and a preparation method thereof, and a yogurt rich in Lactobacillus rhamnosus is prepared. However, there are large differences in the activity of the existing known Lactobacillus rhamnosus. Among them, invention patent CN109536415B discloses a Lactobacillus rhamnosus and its application, and the strain is used as an additive Lactobacillus rhamnosus freeze-dried powder with strong resistance to digestive tract adverse environment and good antibacterial properties in the preparation of food, health food or pharmaceutical composition; However, the antibacterial activity of the Lactobacillus rhamnosus is weak, and the original supernatant of Lactobacillus rhamnosus has no inhibitory activity against Escherichia coli, Staphylococcus aureus, Salmonella typhimurium, Listeria and other strains, and only has a certain antibacterial activity after being concentrated 5 times.

[0004] Therefore, obtaining a strain of Lactobacillus rhamnosus that has strong resistance to adverse digestive tract environment, good antibacterial properties, and can be fermented to prepare fermented milk has become an urgent problem that current probiotic product producers need to solve. Summary of the invention

[0005] In view of the above technical problems, the primary object of the present invention is to provide a Lactobacillus rhamnosus FMBL L23004 CNN, which was deposited in the China Center for Type Culture Collection on June 26, 2023, with a deposit number of CCTCC NO: M 20231099.

[0006] The second object of the present invention is to provide a bacterial agent containing the Lactobacillus rhamnosus FMBL L23004CNN.

[0007] Preferably, the Lactobacillus rhamnosus FMBL L23004 CNN or the bacterial agent, the Lactobacillus rhamnosus FMBL L23004 CNN or the bacterial agent has the following properties:

[0008] (1) It has the potential to inhibit pathogenic microorganisms;

[0009] (2) Have bile salt tolerance;

[0010] (3) Acid resistance;

[0011] (4) Ability to utilize carbohydrates.

[0012] The third object of the present invention is to provide the use of the Lactobacillus rhamnosus FMBL L23004 CNN in the preparation of drugs for inhibiting pathogenic bacteria.

[0013] Preferably, the pathogenic bacteria are one or more of enteropathogenic Escherichia coli, enterotoxigenic Escherichia coli, Salmonella enterica subspecies Typhimurium, enterohemorrhagic Escherichia coli, Listeria monocytogenes, and Salmonella enterica subspecies.

[0014] The fourth object of the present invention is to provide a medicine for preventing and / or treating digestive system diseases, wherein the medicine comprises the Lactobacillus rhamnosus FMBL L23004 CNN or a culture of the Lactobacillus rhamnosus FMBL L23004 CNN or the bacterial agent.

[0015] The fifth object of the present invention is to provide the use of the Lactobacillus rhamnosus FMBL L23004 CNN or the culture of the Lactobacillus rhamnosus FMBL L23004 CNN or the bacterial agent in the preparation of food, food additives or health products.

[0016] The sixth object of the present invention is to provide the use of the Lactobacillus rhamnosus FMBL L23004 CNN or the culture of the Lactobacillus rhamnosus FMBL L23004 CNN or the bacterial agent in the preparation of yogurt or yogurt starter.

[0017] The seventh object of the present invention is to provide a yogurt starter, wherein the yogurt starter comprises the Lactobacillus rhamnosus FMBL L23004 CNN.

[0018] The eighth object of the present invention is to provide a yogurt obtained by fermenting the Lactobacillus rhamnosus FMBL L23004CNN.

[0019] The beneficial effects of the present invention are:

[0020] (1) The present invention provides a Lactobacillus rhamnosus FMBLL23004CNN, which was deposited in the China Center for Type Culture Collection on June 26, 2023, with a deposit number of CCTCC NO: M20231099.

[0021] (2) The Lactobacillus rhamnosus FMBL L23004 CNN has an antibacterial effect and can inhibit six pathogenic microorganisms including enteropathogenic Escherichia coli, enterotoxigenic Escherichia coli, Salmonella enterica subspecies typhimurium, enterohemorrhagic Escherichia coli, Listeria monocytogenes, and Salmonella enterica subspecies enterica; and can be used to prepare drugs, foods, or food additives for inhibiting pathogenic bacteria;

[0022] (3) The Lactobacillus rhamnosus FMBL L23004 CNN also has bile salt resistance, acid resistance and the ability to metabolize carbohydrates;

[0023] (4) The Lactobacillus rhamnosus FMBL L23004 CNN has a good ability to utilize glucose, lactose, oligofructose and oligogalactose, can be used to inhibit diarrhea, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Colony image of Lactobacillus rhamnosus FMBL L23004 CNN

[0025] Note: A. Colony morphology; B. Cell morphology under Gram staining microscope

[0026] Figure 2 Phylogenetic tree DETAILED DESCRIPTION

[0027] The present invention will be further described below in conjunction with the accompanying drawings and embodiments. The following embodiments are only illustrative, and the present invention is not limited to these examples.

[0028] It should be noted that in the following examples, the culture medium formula used is as follows:

[0029] MRS medium: peptone 10.0 g, beef extract 10.0 g, yeast extract 5.0 g, glucose 20.0 g, Tween 80 1.0 mL, K2HPO4 2.0 g, sodium acetate 5.0 g, diammonium hydrogen citrate 2.0 g, MgSO4·7H2O 0.58 g, MnSO4·4H2O 0.25 g, agar powder 18.0 g, deionized water 1000 mL;

[0030] PYG medium (for culturing strain CGMCC 1.9136): peptone 10.0 g, yeast extract 5.0 g, glucose 1.0 g, agar powder 18.0 g, deionized water 1000 mL;

[0031] TSA medium (for culturing strain CGMCC 1.10754): 15.0 g tryptone, 5.0 g soy peptone, 5.0 g sodium chloride, 18.0 g agar powder, 1000 mL deionized water;

[0032] Nutrient agar medium (used for culturing strains CICC10411, CICC10420, CICC10421, CICC21530): peptone 5.0 g, beef extract 3.0 g, sodium chloride 5.0 g, agar powder 18.0 g, deionized water 1000 mL.

[0033] Table 1 Pathogenic bacteria and culture medium

[0034]

[0035] Example 1: Isolation and identification of strains

[0036] Fresh stool samples were collected from healthy children in Yining City, Xinjiang Uygur Autonomous Region. The strains were cultured and isolated under anaerobic conditions by gradient dilution plating method. One strain was selected according to the colony characteristics and cell morphology and named FMBL L23004 CNN.

[0037] The strain DNA was extracted using a bacterial genomic DNA rapid extraction kit, and PCR amplification was performed using groEL gene primers (GroEL-Lac-F: 5'-GCY GGT GCWAAC CCN GTT GG-3', GroEL-Lac-R: 5'-AAN GTN CCV CGVATC TTGTT-3'). The product was sent to Suzhou GeneWeizhi Biotechnology Co., Ltd. for sequencing.

[0038] The colonies are round, milky white, convex in the middle, smooth and opaque, with neat edges and a sticky texture ( Figure 1 A); Gram-positive rod-shaped ( Figure 1B) Pure culture, the obtained sequence was submitted to the GenBank database for BLAST online comparison and similar sequences were downloaded to construct a phylogenetic tree. The results showed that the strain FMBL L23004 CNN is Lactobacillus rhamnosus FMBL L23004 CNN, Latin name: Lacticaseibacillus rhamnosus FMBL L23004 CNN, deposited in the China Center for Type Culture Collection on June 26, 2023, with the deposit number CCTCC NO: M 20231099, and the deposit address is: Wuhan University, Wuhan, China, Tel: (027)-68754052, E-mail: cctcc@whu.edu.cn.

[0039] In the following examples, Lacticaseibacillus rhamnosus FMBLL23004 CNN is abbreviated as Lactobacillus rhamnosus FMBL L23004 CNN.

[0040] Example 2: Anti-diarrhea effect of Lactobacillus rhamnosus FMBLL23004 CNN

[0041] 1. Experimental Methods

[0042] Pathogenic indicator bacteria: enteropathogenic Escherichia coli (Escherichia coil EPEC O127:K63 CICC10411), enterotoxigenic Escherichia coli (Escherichia coil ETEC O78:K80 CICC 10421), Salmonella enterica subsp. enterica serovar Typhimurium CICC 10420), and enterohemorrhagic Escherichia coli (Escherichia coil EHEC O157:H7 CICC 21530) were purchased from China Industrial Microbiological Culture Collection Center, and Listeria monocytogenes (Listeria monocytogenes CGMCC 1.9136) and Salmonella enterica subsp. Enterica CGMCC1.10754 were purchased from China General Microbiological Culture Collection Center.

[0043] (1) Preparation of indicator bacterial suspension: The six indicator bacteria were inoculated into the corresponding liquid culture medium, cultured at 37°C for 18 h, centrifuged, washed, and then the concentration of the bacterial suspension was adjusted to 7 log CFU / mL with sterile saline.

[0044] (2) Preparation of fermentation supernatant: The experimental strain was inoculated into MRS liquid culture medium at a 2% inoculum, cultured at 37°C for 24 h, centrifuged, and the supernatant was filtered with a 0.22 μm sterile filter membrane to obtain a cell-free fermentation supernatant.

[0045] (3) Determination of antibacterial properties by Oxford cup method: Take 100 μL of indicator bacteria suspension and spread it evenly on the corresponding solid culture medium. Place 3 sterile Oxford cups at equal distances, add 200 μL of fermentation supernatant and place in a 4°C refrigerator for diffusion for 4 hours. After constant temperature culture at 37°C for 24 hours, observe and measure the diameter of the inhibition zone, and take the average value of the results.

[0046] 2. Experimental results

[0047] The antibacterial activity of Lactobacillus rhamnosus FMBL L23004 CNN against different strains is shown in Table 3. Lactobacillus rhamnosus FMBL L23004 CNN can inhibit the growth of indicator bacteria.

[0048] Table 3 Analysis of the antibacterial activity of Lactobacillus rhamnosus FMBL L23004 CNN against different strains

[0049]

[0050] Note: Different letters in the same column represent significant differences (P<0.05)

[0051] Example 3. Probiotic properties of Lactobacillus rhamnosus FMBL L23004 CNN

[0052] 1. Experimental Methods

[0053] (1) Evaluation of acid resistance of Lactobacillus rhamnosus FMBL L23004 CNN

[0054] The pH of the MRS liquid medium was adjusted to 2.5, 3.5 and 4.5 with 1 mol / L HCl and sterilized. After the strain FMBLL23004 CNN was activated twice, it was inoculated into MRS liquid medium with different pH values ​​at 2%, cultured at 37°C for 2h and 4h, respectively, and gradient dilution was performed. The dilution was evenly spread on the MRS solid plate and cultured anaerobically at 37°C for 24h. The viable bacteria were counted and the experiment was repeated 3 times.

[0055] (2) Evaluation of bile salt tolerance of Lactobacillus rhamnosus FMBL L23004 CNN

[0056] Supplement pig bile salt to prepare sterile MRS liquid culture medium with final concentrations of 0.1%, 0.3% and 0.5%, respectively. After activating the strain for two generations, inoculate at 2%, culture anaerobically at 37°C, take samples after 2h and 4h, spread them on MRS solid plates with gradient dilutions, culture anaerobically at 37°C for 24h, and count the viable bacteria. The experiment was repeated three times.

[0057] (3) Self-aggregation ability and hydrophobicity of Lactobacillus rhamnosus FMBL L23004 CNN

[0058] Self-aggregation ability: After centrifugation, the activated strain was washed twice with an equal volume of PBS buffer and resuspended. The OD of the bacterial suspension was adjusted. 600 0.6±0.05 (A0). Take 6 mL of bacterial suspension to a 20 mL test tube, vortex for 2 min, let stand at room temperature for 2 h, and take 1 mL of supernatant to measure OD 600 The experiment was repeated three times, and the self-agglutination ability was calculated according to the following formula.

[0059] Self-aggregation ability (A%) = (1-A1 / A0) × 100%

[0060] Hydrophobicity: Take 3mL of the above OD 600 The bacterial suspension with an A0 of 0.6 ± 0.05 was vortexed with 1 mL of xylene for 30 seconds, left to rest for 10 seconds, and then vortexed again for 30 seconds. The OD of the aqueous phase was measured after standing at room temperature for 2 hours. 600 (A t The experiment was repeated three times, and the hydrophobicity of the strain cell surface was calculated according to the following formula.

[0061] Surface hydrophobicity (CSH%) = [1-(A0-A t ) / A0]×100%

[0062] (4) Evaluation of the survival ability of Lactobacillus rhamnosus FMBL L23004 CNN in simulated gastrointestinal fluid digestion

[0063] After activation, Lactobacillus rhamnosus FMBL L23004 CNN was inoculated into MRS liquid medium at a 2% inoculum and cultured anaerobically at 37°C for 18h. Centrifuged at 6000r / min for 10min and washed the strain cells twice with PBS, then resuspended in an equal amount of artificial simulated gastric juice (pH2.5, 0.3% pepsin) and allowed to stand in an anaerobic box at 37°C for 3h. After treatment with simulated gastric juice, centrifuged again and washed three times with PBS, resuspended in an equal amount of artificial intestinal juice (pH7.4, 0.3% bile salt, 0.1% trypsin), and allowed to stand in an anaerobic box at 37°C for 3h, 6h, and 9h, respectively, for gradient dilution. The experiment was repeated three times, and the number of viable bacteria was calculated by the colony plate count method.

[0064] (5) Characteristics of carbohydrate utilization by Lactobacillus rhamnosus FMBL L23004 CNN

[0065] In the experimental group, the mother liquor of different sugars was sterilized by filtering with a 0.22 μm sterile filter membrane and then replaced with glucose in the liquid MRS medium. The MRS medium was used as the positive control group, and the MRS medium without sugar was used as the blank control. The activated bacterial liquid was washed and resuspended with sterile PBS, and inoculated into the experimental group and control group culture medium at a ratio of 2%. The culture was anaerobically cultured at 37°C for 24 hours, and the OD was measured. 600 ,The experiment was set up in three parallels.

[0066] 2. Results

[0067] (1) Characteristics of carbohydrate utilization by Lactobacillus rhamnosus FMBL L23004 CNN

[0068] Lactobacillus rhamnosus FMBL L23004 CNN has a good utilization effect on inulin, resistant starch, fructooligosaccharides, xylooligosaccharides, soybean oligosaccharides, D-raffinose, stachyose, isomaltooligosaccharides, galacto-oligosaccharides, lactose and glucose, and has a poor metabolic ability for D-trehalose and maltodextrin, as shown in Table 4.

[0069] Table 4 The ability of Lactobacillus rhamnosus FMBL L23004 CNN to utilize carbohydrates

[0070]

[0071] Note: Different letters represent significant differences (P<0.05)

[0072] (2) Acid and bile resistance of Lactobacillus rhamnosus FMBL L23004 CNN

[0073] Acid and bile salt tolerance is a prerequisite for strains to survive, grow and play a probiotic role in the intestine. These characteristics are also used as one of the selection criteria for evaluating lactic acid bacteria strains as candidate strains for probiotic development. Generally speaking, the bile salt concentration in human bile ranges from 0.3% to 0.5%, so tolerance to bile is an important feature that enables lactic acid bacteria to survive, grow and remain active in the small intestine. As shown in Table 5, after tolerating bile salts for 4 hours, the number of viable bacteria of Lactobacillus rhamnosus FMBL L23004 CNN can reach 4.86log CFU / mL. As shown in Table 6, the strain has good tolerance to acid, and still has a survival rate of more than 10% under pH2.5 treatment after 4 hours.

[0074] Table 5 Tolerance of Lactobacillus rhamnosus FMBL L23004 CNN to bile salts

[0075]

[0076] Note: Different letters in the same row represent significant differences (P<0.05)

[0077] Table 6 Acid tolerance of Lactobacillus rhamnosus FMBL L23004 CNN

[0078]

[0079] Note: Different letters in the same row represent significant differences (P<0.05)

[0080] (3) Analysis of the autoagglutination and hydrophobicity of Lactobacillus rhamnosus

[0081] As shown in Table 7, Lactobacillus rhamnosus FMBL L23004 CNN has good self-aggregation and hydrophobicity.

[0082] Table 7 Analysis of the self-agglutination and hydrophobicity of antibacterial Lactobacillus rhamnosus

[0083]

[0084] (4) Evaluation of the survival ability of antibacterial Lactobacillus rhamnosus FMBL L23004 CNN in gastric and intestinal fluids

[0085] As shown in Table 8, after being treated with gastric juice for 3 h, the survival rate of Lactobacillus rhamnosus FMBL L23004 CNN can reach 7.66 log CFU / mL. After being treated with intestinal juice for 6 h, the survival rate of the strain decreased significantly, and the survival rate was 3.35 log CFU / mL.

[0086] Table 8 Evaluation of the survival ability of Lactobacillus rhamnosus FMBL L23004 CNN during simulated digestion

[0087]

[0088] Note: Letters represent significant differences (P<0.05)

[0089] Example 4: Antibiotic sensitivity

[0090] The Lactobacillus rhamnosus FMBL L23004 CNN provided by the present invention is a probiotic isolated from fresh feces of healthy adults, and its safety and effectiveness are guaranteed from the source of bacteria. In addition, after colonization and reproduction in the human intestinal environment, the Lactobacillus rhamnosus FMBL L23004 CNN provided by the present invention only adheres to the intestinal epithelial cells of the host, can become a biological barrier of the intestinal mucosa, improve the barrier capacity of the host intestinal mucosa, and can directly act on the human body in the form of live bacteria, thereby ensuring safety.

[0091] 1. Experimental Methods

[0092] After 2% inoculation of Lactobacillus rhamnosus FMBL L23004 CNN was cultured anaerobically at 37°C for 24 h, 100 μL (about 1×10 7 cfu / mL) bacterial solution was spread on the surface of MRS solid culture medium, and drug-sensitive paper sheets (Oxoid, UK) were lightly pressed against the middle of the culture medium, and cultured anaerobically at 37°C for 24 hours. The antibacterial performance of the drug-sensitive sheets was observed, and the diameter of the antibacterial zone of the drug-sensitive sheets was measured. The information of the drug-sensitive sheets is shown in Table 9.

[0093] Table 9 Drug sensitivity paper information

[0094]

[0095]

[0096] 2. Experimental results

[0097] As shown in Table 10, it can be seen that Lactobacillus rhamnosus FMBL L23004 CNN is resistant to gentamicin, acamycin, vancomycin, teikanin, norfloxacin, polymyxin, kanamycin and ciprofloxacin, and is sensitive to penicillin, ampicillin, cephalosporin, clindamycin, tetracycline, minocycline, chloramphenicol, rifampicin, amoxicillin and erythromycin.

[0098] Table 10 Antibiotic sensitivity of the two strains

[0099]

[0100] Note: R: resistant; I: moderately sensitive; S: sensitive

[0101] In summary, the present invention provides a Lactobacillus rhamnosus FMBL L23004 CNN, which was deposited in the China Center for Type Culture Collection on June 26, 2023, with a deposit number of CCTCCNO: M 20231099. The rhamnosus lactobacillus FMBL L23004 CNN has an antibacterial effect and can inhibit six pathogenic microorganisms including enteropathogenic Escherichia coli, enterotoxigenic Escherichia coli, enterotoxigenic Salmonella enterica subspecies typhimurium, enterohemorrhagic Escherichia coli, Listeria monocytogenes, and enterotoxigenic Salmonella enterica subspecies; the rhamnosus lactobacillus FMBL L23004 CNN can be used to prepare drugs, foods, or food additives for inhibiting pathogenic bacteria; the rhamnosus lactobacillus FMBL L23004 CNN also has bile salt resistance, acid resistance, and the ability to metabolize carbohydrates; the rhamnosus lactobacillus FMBL L23004 CNN has good utilization capabilities for glucose, lactose, oligofructose, and oligogalactose, can be used to inhibit diarrhea, and has broad application prospects.

Claims

1. A Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus )FMBL L23004 CNN, deposited in China Center for Type Culture Collection on June 26, 2023, with the deposit number CCTCC NO: M 20231099.

2. A bacterial agent, characterized in that Contains the Lactobacillus rhamnosus FMBL L23004 CNN according to claim 1.

3. A drug for preventing and / or treating digestive system diseases, characterized in that: The medicine comprises the Lactobacillus rhamnosus FMBL L23004 CNN as claimed in claim 1 or the bacterial agent as claimed in claim 2.

4. Use of the Lactobacillus rhamnosus FMBL L23004 CNN as claimed in claim 1 or the bacterial agent as claimed in claim 2 in the preparation of food, food additives or health products.

5. Application of Lactobacillus rhamnosus FMBL L23004 CNN as claimed in claim 1 or the bacterial agent as claimed in claim 2 in preparing yogurt or yogurt starter.

6. A yogurt starter, characterized in that: The yogurt starter comprises the Lactobacillus rhamnosus FMBL L23004 CNN according to claim 1.

7. A yogurt, characterized in that: The method is obtained by fermenting the Lactobacillus rhamnosus FMBL L23004 CNN according to claim 1.

Citation Information

Cited By

  • Application of lactobacillus rhamnosus FMBL L23004 CNN in fermentation of prunus salicina and prunus salicina product prepared from lactobacillus rhamnosus FMBL L23004 CNN

    CN119867234A

  • Application of lactobacillus rhamnosus FMBL L23004 CNN in preparation of medicine for preventing or treating diabetes

    CN119950562A